Summary

Overview
The global arthropod-borne viral infections testing market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Arboviral diseases are infections caused by viruses spread among humans through the bites of arthropods. Common arthropods through which diseases are spread are mosquitoes and ticks.
California encephalitis, chikungunya, dengue, eastern equine encephalitis, St. louis’ encephalitis, west nile, yellow fever, and zika are examples of arboviral diseases spread among humans by the bite of infected arthropods (insects) such as mosquitoes and ticks.
Other diseases spread by infected arthropod bites that are not viral, such as Lyme disease (a bacterial infection) and babesiosis (a parasitic infection), are not arboviral. These diseases usually appear during summer, when mosquitoes and ticks are busy. Arboviral infection appears to be more common in young children and the elderly.
Market Dynamics: Drivers
Increasing Government Initiatives
The demand for the arthropod-borne viral infections testing market is driven by multiple factors.
To reduce the danger of arthropod-borne viral infections, governments worldwide are collaborating with health groups. With significant outbreaks being reported worldwide in recent years, the focus on these diseases has increased as a matter of public safety.
For instance, in 2022, Global New Infections Surveillance (GEIS), a part of the United States Armed Forces Health Surveillance Branch, will undertake a pilot program to identify emerging infectious diseases and decrease risk. A global laboratory network to improve global health security is projected to do this.
Furthermore, the mortality rate among patients suffering from encephalitis has been as high as 30%. In addition, the JEV can have various adverse effects, such as long-term neurologic or psychological consequences. This may affect 30?50% of the patient population. The market for arthropod-borne viral infections is expected to grow in the next years as the number of molecular diagnostic approaches for identifying the illness grows.
A pilot program to identify new infectious illnesses and reduce risk is scheduled to begin in the spring of 2022 and is financed by Global New Infectious Surveillance (GEIS), a branch of the U.S. Armed Forces Health Surveillance Branch, and will run through March 2024.
Also, in March 2022, with great pleasure, the World Health Organization announced that the Global Arbovirus Initiative will get underway. To improve the coordination, communication, capacity-building, research, readiness, and reaction required to reduce the increasing risk of epidemics caused by these diseases, this integrated project will assemble a coalition of important partners.
Restraints
Factors such as the high cost of diagnostics tests, lack of infrastructure and resources, shortage of in vitro facilities, and lack of awareness about several infectious diseases are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The arthropod-borne viral infections testing market is segmented based on test type, disease type, end-user, and region.
The RT-PCR-based tests segment accounted for approximately 37.6% of the arthropod-borne viral infections testing market share
The RT-PCT-based tests segment is expected to hold the largest market share over the forecast period. Due to its advantages, the RT-PCR-based tests segment is likely to dominate the arbovirus testing market over the forecast period. The detection limit is a fundamental distinction between ELISA (Enzyme-linked immunosorbent assay) and PCR assays.
An ELISA-based method typically has a detection limit of 104-106 CFU/ml, but a PCR method can detect in the 103 CFU/ml range. Because of the difference in detection limits, an ELISA approach normally requires a longer enrichment time.
Even in terms of sensitivity, the PCR approach outperforms the ELISA technique. Compared to ELISA, the waste produced in laboratories using the PCR technique is smaller. As a result of these factors, RT-PCR-based tests are expected to dominate the arbovirus testing market over the forecast period.
Next-generation diagnostic test for dengue virus detection using an ultrafast plasmonic colorimetric RT-PCR strategy. For instance, in MAY 2022, Anitoa Systems announced the availability of an RT-PCR solution for testing the dengue virus. This turn-key solution, available from Anitoa systems, includes one of a family of 4-6 channel small foot-print real-time PCR instruments called the Maverick qPCR, with a one-step multiplex RT-PCR reagent offered in lyophilized format. Lyophilized reagents are easy to transport, without the need for refrigeration.
Geographical Analysis
North America accounted for approximately 43.7% of the arthropod-borne viral infections testing market share
North America region is expected to hold the largest market share over the forecast period. Owing to the region's established economy, rising healthcare spending, and high adoption of technologically advanced products. As a result, North America will lead the arbovirus testing market over the projected period.
In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market.
Also, several product launches in the market will lead to lucrative growth of the market. For instance, in 2021, The Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit is intended to detect immunoglobulin G (IgG) antibodies to qualitatively detect immunoglobulin G (IgG) antibodies SARS-CoV-2 in human serum or plasma, according to Agilent Technologies Inc.
The region's high proportion is caused by several factors, including the expanding prevalence of arboviral infections like West Nile Virus and the increasing burden of Neglected Tropical infections (NTDs). For instance, in 2023, the Centres for Sickness Control & Prevention (CDC) reported that 2,406 cases of West Nile virus sickness were reported in the United States.
In addition, elements such as the shifting vector distribution?primarily those of Aedes aegypti and Aedes albopictus?combined with rising temperatures and increased humidity due to climate change, will drive market expansion in the years to come.
Furthermore, advancements in various arthropod-borne viral infections testing devices from established key players, in the United States, are likely to drive the market growth in North America.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the arthropod-borne viral infections testing market. In collaboration with governments around the world, pharmaceutical and biotech businesses are working to tackle the COVID-19 outbreak, from vaccine research to overcoming supply chain hurdles.
In the R&D pipeline, there are around 115 vaccine candidates and another 155 compounds. Furthermore, routinely used medications, such as hydroxychloroquine, have significantly increased the demand for COVID-19 treatment.
Furthermore, demand for COVID-19 management pharmaceuticals has increased, which is projected to present a significant opportunity for drug producers, as many developed countries need these medications. The pharmaceutical and biotechnology industries are expected to increase significantly in the next years due to the growing demand for COVID-19 vaccines and treatment medications.
Market Segmentation
By Test type
- ELISA Based Tests
- RT-PCR Based Tests
- Others
By Disease type
- Dengue
- Chikungunya
- St. Louis Encephalitis
- Yellow Fever
- California Encephalitis
- Eastern Equine Encephalitis
- Powassan
- West Nile
- Zika
By End-Users
- Hospitals
- Research Centers
- Diagnostic Centers
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the arthropod-borne viral infections testing’ market include Bio-Techne, Agilent Technologies, ThermoFisher Scientific, NovaTec Immundiagnostica, Euro immune AG, Abbott Laboratories, Bio-Rad, Merck, Acrobiosystems, Elabscience among others.
Key Developments
- On May 9, 2024, The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million) in four projects for the development of new drugs for malaria and neglected tropical diseases.
- On May 25, 2023, Astellas Pharma Inc. announced its contribution to the Global Health Innovative Technology Fund, which will fund the development of medications, diagnostic tools, and vaccinations that assist in fighting various infectious illnesses, especially underappreciated tropical diseases.
- On July 14, 2022, Mylab Discovery Solutions' newly launched disease testing kit, the ‘PathoDetect Extended Monsoon Fever Panel demonstrated high sensitivity and specificity and efficiently differentiates Malaria, Chikungunya, Dengue, Zika, Leptospirosis, Salmonellosis bacterial species, and Leishmaniasis parasite.
- On November 5, 2021, dengue fever diagnostic kits were developed by Achico, a healthcare technology company based in Switzerland. This new test kit would be based on the company's DNA aptamer technology platform, which effectively diagnoses COVID-19.
Why Purchase the Report?
- To visualize the arthropod-borne viral infections testing market segmentation based on test type, disease type, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of arthropod-borne viral infections testing’ market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Test type mapping is available in excel consisting of key test types of all the major players.
The arthropod-borne viral infections testing market report would provide approximately 62 tables, 59 figures, and 182 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Test type
3.2. Snippet by Disease type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Government Initiatives
4.1.2. Restraints
4.1.2.1. The High Cost of the Diagnostic Tests
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Test type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
7.1.2. Market Attractiveness Index, By Test Type
7.2. ELISA Based Tests*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. RT-PCR Based Tests
7.4. Others
8. By Disease type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
8.1.2. Market Attractiveness Index, By Type
8.2. Dengue *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chikungunya
8.4. St. Louis Encephalitis
8.5. Yellow Fever
8.6. California Encephalitis
8.7. Eastern Equine Encephalitis
8.8. Powassan
8.9. West Nile
8.10. Zika
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Centers
9.4. Diagnostic Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. South Korea
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Bio Techne*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Agilent Technologies
12.3. ThermoFisher Scientific
12.4. NovaTeclmmundiagnostica
12.5. Euroimmun AG
12.6. Abbott Laboratories
12.7. Bio-Rad
12.8. Merck
12.9. Acrobiosystems
12.10. Elabscience
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us